Strategic partnership impact Leverage the 2023 strategic partnership with DNB Bank to position as a cross-border life sciences advisor, offering integrated strategy, M&A, and capital markets execution to biotech, pharmaceutical, and medtech clients seeking global reach.

Growth and expansion opportunities Target mid-market life science companies navigating strategic reviews, parlaying past advisory relationships such as with Admera Health and Scandion Oncology to expand service scope into strategic alternatives, partnerships, and exit planning.

Financial profile signals Operate with a lean team size and modest revenue range, suggesting high-potential upsell opportunities around scalable advisory packages, retainer-based strategy work, and project-based M&A execution for growing organizations.

Industry credibility Capitalize on niche expertise in life sciences strategy and investment banking to win mandates from biotech, pharma, and medical technology firms seeking unbiased, end-to-end support for development, commercialization, and market share maintenance.

Technology and data capabilities Promote data-driven advisory with a tech stack including analytics and reporting tools to differentiate services, enabling enhanced due diligence, market assessments, and performance tracking for strategic and financial transactions.